The study compound may potentially be used for the treatment of heart and vascular diseases and metabolic diseases. In metabolic diseases, something goes wrong with the conversion of nutrients into energy, or nutrients are not properly broken down. Heart and vascular diseases and metabolic diseases are a group of long-term diseases.
The trial consists of four parts: Part A, Part B, Part C and Part D. You can only participate in one part. The following information concerns Part A.
During this clinical trial, we will investigate how safe the study compound is and how well it is tolerated. We will also investigate how quickly and to what extent the study compound is absorbed, transported, and eliminated from the body. In addition we will also look if the study compound has an effect on an important protein involved in inflammation.
In the trial we will compare the effects of the study compound with the effects of a placebo. A placebo is a compound without any active ingredient.
You will be given the study compound (or placebo) as capsules by mouth with water.
You will receive the study compound once.
During the trial, your heart will be monitored continuously from 18 hours before administration of the study compound until 36 hours thereafter. You will have sticky patches (electrodes) attached to your chest that are connected to a device. At various times, you will have to lie still for 10 minutes without moving, talking or sleeping. You also cannot listen to music, watch TV or use a laptop or phone. However, apart from these times, you may do so.
At the start of the medical screening, you should only have consumed water for 4 hours. This means that before your potential participation in the trial, we will already ask you not to eat for a period of time. You have not yet signed the form for participation in the trial. After the medical screening it will be announced whether you can participate.
All (potential) medicines can cause side effects. Because the compound has not yet been administered to humans, there are currently no known side effects in humans. In rare cases (<0.1%), serious side effects can occur during the first administration to humans. The compound has already been extensively tested in the laboratory and on animals. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects based on these animal tests. This information will also be discussed with you at the start of the medical screening. You can then ask the screening physician or nurse any question you may have. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.